Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide

Chinese Academy of Sciences36 enrolled

Overview

The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.

Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Healthy

Eligibility

Sex: MALEMin age: 21 YearsMax age: 27 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * nonsmokers and in good health Exclusion Criteria: * family history of diabetes mellitus * taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study

Locations (1)

The second hospital to Liaoning University of TCM

Shenyang, Liaoning, China

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.